Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C

Rodríguez-Lojo, Romina; Almagro, Manuel; Barja, Juan; Piñeyro, F.; Pérez-Varela, L.; Pozo, Jesús del; Yebra-Pimentel, M. Teresa; Fonseca, Eduardo

doi:10.1155/2010/230417

Cited by 9 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Le délai de survenue est variable entre 2 semaines après le début de traitement jusqu'à 30 mois après son arrêt [5,10,16]. La maladie survient en général dans les 6 mois après l'arrêt du traitement [8].…”

Section: Discussionunclassified

“…Les signes généraux sont rarement présents [6], ils ont peu de valeur diagnostique. En effet, ils peuvent être attribués à tort aux effets indésirables de l'interféron, aux manifestations de l'hépatite virale C, ce qui peut laisser penser que le nombre de cas de sarcoïdose induite est sous estimé [16].…”

Section: Discussionunclassified

“…Cependant, des cas de sarcoïdoses ont été observés chez des malades suivis pour VHC et non traités par interféron, ce qui laisse supposer un rôle propre du virus [8]. Le rôle de la ribavirine paraît faible, certains auteurs suggèrent son effet potentialisateur dans la réponse immunitaire [4,8,16]. Toutefois, aucun cas de sarcoïdose n'a été notifié avec ce traitement [6,7].…”

Section: Discussionunclassified

See 2 more Smart Citations

Sarcoïdose chez un patient traité par interféron pégylé pour une hépatite chronique C

Moudden

Ziadi

Bouzidi

et al. 2014

Revue de Pneumologie Clinique

View full text Add to dashboard Cite

Section: Discussionunclassified

See 1 more Smart Citation

Sarcoïdose chez un patient traité par interféron pégylé pour une hépatite chronique C

Moudden

Ziadi

Bouzidi

et al. 2014

Revue de Pneumologie Clinique

View full text Add to dashboard Cite

“…She has being followed-up for one year with no signs of recurrence. Subcutaneous sarcoidosis (SS) is an unusual and specific subtype of nodular sarcoidosis [1]. It was first described by Darier and Roussy in 1904 [2].…”

Section: Communicationmentioning

confidence: 99%

A middle-age woman with subcutaneous plaque and hilar adenopathies

2011

View full text Add to dashboard Cite

AbstractSubcutaneous sarcoidosis (SS) is an unusual and specific subtype of nodular sarcoidosis 1. The presence of SS with no elements of systemic manifestations is a rare condition: it is reported only in 1.4% to 6% of patients with systemic sarcoidosis, with the trunk being the most predilected area. Such cases with rare presentation are challenging for physicians because it can mimic several chronic infections, amyloidosis, hypothyroidism, lysosomal storage diseases and other conditions. Typical imaging (specially bilateral hilar adenopathies), histological exam and laboratory findings are the baseline to establish the diagnosis of sarcoidosis. In our case, the presence of subcutaneous manifestations avoided the performance of invasive procedures to get confirmation from other target organs: The epithelioid cells granulommas in subcutaneous fat and the representative radiological images were enough features to make the certain diagnosis. The first-line therapy for SS is oral steroids (20–40 mgr/day) with responses observed only 4–8 weeks after initiation of the treatment2. Prognosis of SS is good with spontaneous remission in some cases; however, when granulommas or fibrosis involves vital organs sarcoidosis can be life-threatening. Physicians should consider diagnosis of SS in patients with clinical suspicious history as sometimes skin manifestations are the first sign of systemic presentation of disease

show abstract

“…Side‐effects are observed in almost 80% of patients treated with combination therapy over the course of treatment, and the appearance of various skin conditions, such as eczematous and lichenoid eruptions and psoriasis, have been reported . Cutaneous sarcoidosis in varying manifestations has also been reported to develop due to PEG IFN and RBV combination therapy …”

Section: Introductionmentioning

confidence: 99%

Cutaneous sarcoidosis in a chronic hepatitis C patient receiving pegylated interferon and ribavirin therapy

Joshita

Shirahata

Yazaki

et al. 2013

Hepatology Research

View full text Add to dashboard Cite

A 61‐year‐old Japanese woman suffered from a small, painful, subcutaneous nodule on the sole of her foot that was 10 mm across in diameter during pegylated interferon (PEG IFN) and ribavirin (RBV) combination therapy for chronic hepatitis C. Skin biopsy revealed multiple non‐caseating granulomas composed of epithelioid histiocytes with multinucleate giant cells, which was consistent with sarcoidosis. Ophthalmologic examination revealed uveitis. Thoracic computed tomography (CT) showed multiple bilateral hilar lymphadenopathies and a diffuse micronodular interstitial pattern of the lungs. Genetic analysis indicated a probable homozygous haplotype of A*02:01‐C*15:02‐B*51:01‐DRB1*16:02‐DQB1*05:02 in human leukocyte antigen regions. The patient was observed carefully without any additional medication because no significant systemic symptoms were noted. Combination therapy was continued for 2 months afterwards. She was asymptomatic for over 3 years of follow up, and repeated hematological and biological investigations and chest CT showed improvement. In conclusion, clinicians should bear sarcoidosis in mind as a complication during PEG IFN and RBV combination therapy. They should also be aware of the usually good prognosis of PEG IFN‐induced cutaneous sarcoidosis in order not to prematurely discontinue a treatment necessary for liver disease; maintenance of PEG IFN treatment may be advised with careful follow up.

show abstract

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C

Cited by 9 publications

References 11 publications

Sarcoïdose chez un patient traité par interféron pégylé pour une hépatite chronique C

Sarcoïdose chez un patient traité par interféron pégylé pour une hépatite chronique C

A middle-age woman with subcutaneous plaque and hilar adenopathies

Cutaneous sarcoidosis in a chronic hepatitis C patient receiving pegylated interferon and ribavirin therapy

Contact Info

Product

Resources

About